Alkem Laboratories Limited

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:53 2024-06-28 EDT			5-day change	1st Jan Change
4,991 ^INR	+1.38%		-2.69%	-4.06%

06-25	Alkem Laboratories Gets 'Voluntary Action Indicated' for Baddi, India Facility; Shares Jump 4%	MT
06-14	Alkem Laboratories Limited Announces Resignation of Dheeraj Sharma as an Independent Director	CI

Alkem Laboratories Limited Announces Resignation of Dheeraj Sharma as an Independent Director

June 14, 2024 at 08:20 am

Alkem Laboratories Limited announced that Dr. Dheeraj Sharma (DIN: 07683375) has vide email dated 14 June, 2024 tendered his resignation as an Independent Director of the Company, due to pre-occupation. Date of cessation is on 14 June, 2024.

Latest news about Alkem Laboratories Limited

Alkem Laboratories Gets 'Voluntary Action Indicated' for Baddi, India Facility; Shares Jump 4%	06-25	MT
Alkem Laboratories Limited Announces Resignation of Dheeraj Sharma as an Independent Director	06-14	CI
Alkem Laboratories Limited Receives an Order-In-Appeal Passed by Joint Commissioner (Appeals-II), Hyderabad Commissionerate, Telangana	06-10	CI
Alkem Laboratories to Invest INR300 Million in HaystackAnalytics	06-06	MT
Alkem Laboratories' Consolidated Profit Soars in Fiscal Q4; Shares Slump 6%	05-30	MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,200 From INR4,470, Keeps at Underperform	05-30	MT
Transcript : Alkem Laboratories Limited, Q4 2024 Earnings Call, May 29, 2024	05-29
Alkem Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-29	CI
Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024	05-29	CI
Alkem Laboratories Limited Receives an Order Passed by Additional Commissioner, Office of Additional Commissioner, Central GST SUB. - Commissionerate, Mohali: Chandigarh	05-15	CI
Alkem Laboratories Limited Receives Order from Assistant Commissioner, GST & Central Excise, Cuttack-II Division, Cuttack and Superintendent, Central GST & Central Excise, Cuttack-II Division, Cuttack	05-07	CI
Alkem Laboratories Limited Receives an Order from Assistant Commissioner, Ghatak 55, Range-14, Division 6, Gujarat	04-30	CI
Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak	04-16	CI
Alkem Laboratories Forms Subsidiary for Medical Devices Business	03-28	MT
Alkem Laboratories Limited Announces Incorporation of Subsidiary Alkem Medtech Private Limited	03-28	CI
Alkem Laboratories Gets 10 Observations from US FDA After Baddi, India Unit Inspection	03-27	MT
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	02-12	MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,470 From INR3,960, Keeps at Underperform	02-12	MT
Transcript : Alkem Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024	02-09
Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024	02-09	CI
Alkem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-09	CI
Indian Equities Close Higher on Friday, Lifted by IT Stocks	01-12	MT
Alkem Laboratories Names Successor to Outgoing CFO	01-12	MT
Alkem Laboratories Limited Announces CFO Changes	01-12	CI
Heritage Global, Investors Acquire Pharmaceutical Plant from Alkem Laboratories	01-11	MT

Chart Alkem Laboratories Limited

Duration

Period

More charts

Company Profile

Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Alkem Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4,991 INR

Average target price

5,195 INR

Spread / Average Target

+4.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALKEM LABORATORIES LIMITED	-4.06%	7.05B
ELI LILLY AND COMPANY	+55.32%	819B
JOHNSON & JOHNSON	-6.75%	351B
MERCK & CO., INC.	+13.56%	329B
ABBVIE INC.	+10.68%	298B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	225B
NOVARTIS AG	+13.31%	217B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	158B

Other Pharmaceuticals